NGM stock shifts to a private biotech pipeline after delisting

Published on 09/30/2026 at 07:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NGM stock now reflects a private biotech reset after USD 142.04 million sold to 26 investors was reported on March 27, 2026. Its pipeline centers on two programs.

NGM, US62921N1006, Illustration mit AI erstellt.

NGM Biopharmaceuticals (ISIN US62921N1006) reported cumulative amount sold of USD 142.04 million to 26 investors in a Form D/A filed on March 27, 2026, according to EdgeChat. The figure gives NGM stock a very different profile from its public-market past: the biotechnology company is now privately held and is rebuilding around a narrow clinical pipeline.

Private funding changes the picture

NGM accepted a USD 1.55 per share cash offer in the take-private completed on April 5, 2024. The transaction valued the company at USD 135.00 million on a fully diluted basis and represented an 80.00 percent premium to the December 29, 2023 closing price, according to EdgeChat.

NGM shares ceased trading on Nasdaq before the market opened on April 5, 2024. The financing structure therefore matters more than a daily quotation: the company announced a USD 122.00 million Series A on July 17, 2024, led by The Column Group.

Two programs carry the pipeline

The relaunch concentrates resources on two clinical programs rather than the ten programs NGM had pursued at its peak. Aldafermin is being developed for primary sclerosing cholangitis, while NGM120 is being studied for hyperemesis gravidarum and cancer cachexia.

NGM's investor-relations page lists the first participant dosed in the EMERALD Phase 2 study of NGM120 on February 24, 2025. The company describes the study as targeting hyperemesis gravidarum in pregnant patients, providing the clearest dated clinical milestone in its current public communications.

NGM stock enters a private phase

The key comparison is between the former public-market structure and the current private model: NGM moved from a Nasdaq-listed company with a USD 1.55 per share take-private value to a privately financed two-program biotech. For investors tracking the historical ticker, the March 27, 2026 Form D/A and the USD 122.00 million Series A mark the more relevant capital milestones than a live share price.